Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed adenocarcinoma of the prostate
• •Disease progression following androgen ablation therapy (hormonal or surgical) by either:
• •* Increase in the product of bidimensional diameters of 1 or more radiographically documented sites of measurable disease OR
• •* Two consecutive increases in PSA documented over a previous reference value
• •* First increase in PSA should occur a minimum of 1 week from the reference value and be confirmed
• •* First PSA value is less than the previous value, then patient is eligible provided next PSA is greater than the second PSA
• •Testosterone levels documented in the castrate range (i.e., less than 30 ng/mL)
• •PATIENT CHARACTERISTICS:
• •Age:
• •18 to 85
• •Performance status:
• •CALGB 0-2
• •Life expectancy:
• •Not specified
• •Hematopoietic:
• •WBC at least 3,000/mm3
• •Platelet count at least 100,000/mm3
• •Hepatic:
• •Bilirubin normal
• •SGOT no greater than 2.5 times upper limit of normal (ULN) if alkaline phosphatase normal OR
• •Alkaline phosphatase no greater than 4 times ULN if SGOT normal OR
• •SGOT no greater than 1.5 times ULN and alkaline phosphatase no greater than 2.5 times ULN
• •Renal:
• •Creatinine no greater than 2.0 mg/dL
• •Cardiovascular:
• •No myocardial infarction within past year
• •No significant change in anginal pattern within past 6 months
• •No New York Heart Association class II-IV heart disease
• •No deep venous thrombosis within past year
• •Other:
• •No significant peripheral neuropathy
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •Not specified
• •Chemotherapy:
• •Prior chemotherapy allowed except taxanes or platinum derivatives
• •Endocrine therapy:
• •See Disease Characteristics
• •At least 4 weeks since prior antiandrogens
• •Radiotherapy:
• •At least 4 weeks since prior radiotherapy
• •Surgery:
• •See Disease Characteristics